Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Eliquis Superiority Claim May Be At Stake In “Complete Response” Letter

Jul 01 2012

• By Cathy Dombrowski

Related Content

<i>Pradaxa</i> Review Shows FDA Doubts About The Power Of REMS To Change Prescribing Practices

Apr 01 2011

Apixaban Shows Mortality Advantage, But Will It Survive FDA Scrutiny?

Sep 05 2011

BMS/Pfizer’s <em>Eliquis</em> On Priority Review Path Toward March 2012 Approval

Nov 29 2011

<em>Xarelto</em> Acute Coronary Syndromes Claim Faces Data Quality Hurdle

May 22 2012

<em>Xarelto</em> Label Expansion Plans Slowed By FDA “Complete Response” On ACS Claim

Jul 01 2012

<em>Eliquis</em> Delay Fuels Speculation About Advisory Committee Meeting

Mar 01 2012

ATLAS Data Not Strong Enough To Support <em>Xarelto</em>’s Use In ACS, FDA Panel Says

May 28 2012

FDA Panel Looks Beyond <em>Xarelto</em>’s Missing Data Problems To Broader Reforms

Jun 04 2012

Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa

Nov 07 2011

Related Companies

Bristol Myers Squibb Company

Pfizer Inc.

Johnson & Johnson

Boehringer Ingelheim GmbH

Additional Topics

Clinical Trials Drug Approval Standards BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window